FrancophonIA/ELRC3.0 huggingface dataset:
English: Co-administration of Symtuza and these anticonvulsants is contraindicated (see section 4.3).
Croatian: Istodobna primjena lijeka Symtuza i ovih antikonvulziva je kontraindicirana (vidjeti dio 4.3).
English: Based on theoretical considerations DRV/COBI is expected to increase these sedative/hypnotic plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih sedativa/hipnotika. (inhibicija CYP3A)
English: Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil in concentrating tenofovir in peripheral blood mononuclear cells (PBMC) (including lymphocytes and other HIV target cells) and macrophages.
Croatian: A učinkovitije od tenofovirdizoproksila koncentrira tenofovir u mononuklearnim stanicama periferne krvi (uključujući limfocite i druge stanice na koje cilja HIV) i makrofagima.
English: Based on theoretical considerations DRV/COBI may increase methadone plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, DRV/KOBI može povisiti plazmatske koncentracije metadona.
English: In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection.
Croatian: Nakon što započnete liječenje HIV infekcije, osim oportunističkih infekcija mogu se javiti i autoimuni poremećaji (stanje u kojem imunološki sustav napada zdravo tjelesno tkivo).
English: Based on theoretical considerations (systemic) dexamethasone is expected to decrease darunavir and/or cobicistat plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će deksametazon (sistemski) sniziti plazmatske koncentracije darunavira i/ili kobicistata. (indukcija CYP3A)
English: The effects of other medicines might be influenced if you take Symtuza.
Croatian: Primjena lijeka Symtuza može utjecati na učinke drugih lijekova.
English: Based on theoretical considerations DRV/COBI may alter warfarin plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, DRV/KOBI može promijeniti plazmatske koncentracije varfarina.
English: Based on theoretical considerations rifampicin is expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će rifampicin sniziti plazmatske koncentracije darunavira i/ili kobicistata i/ili tenofoviralafenamida. (indukcija CYP3A i/ili P-glikoproteina)
English: Symtuza has not been investigated in patients with hepatic impairment.
Croatian: Lijek Symtuza nije ispitivan u bolesnika s oštećenjem jetrene funkcije.
English: Your doctor should do blood tests before you start Symtuza.
Croatian: Prije početka uzimanja lijeka Symtuza liječnik Vas treba uputiti da napravite krvne pretrage.
English: • enlargement of breasts
Croatian: • povećanje dojki
English: In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical trials with darunavir co-administered with low dose ritonavir.
Croatian: Nadalje, u kliničkim ispitivanjima u kojima se darunavir primjenjivao istodobno s niskom dozom ritonavira primijećena je reaktivacija herpesa simpleks i herpesa zoster.
English: Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mL Missing data during window but on trial Virologic response (HIV-1-RNA < 50 copies/mL; Snapshot Analysis) by subgroup, n/N (%)
Croatian: Virološki odgovor (HIV-1-RNK <50 kopija/mL; Snapshot analiza) prema podskupinama, n/N (%) Dob <50 godina ≥50 godina Spol Muški Ženski
English: Co-administration of oral midazolam or triazolam and Symtuza is contraindicated (see section 4.3).
Croatian: Istodobna primjena midazolama peroralno ili triazolama i lijeka Symtuza je kontraindicirana (vidjeti dio 4.3).
English: The bioavailability of the components of Symtuza was not affected when administered orally as a split tablet compared to administration as a tablet swallowed whole.
Croatian: Primjena prepolovljene tablete kroz usta u usporedbi s tabletom koja je progutana cijela, nije utjecala na bioraspoloživost komponenti lijeka Symtuza.
English: Based on theoretical considerations DRV/COBI is expected to increase these calcium channel blocker plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih blokatora kalcijevih kanala. (inhibicija CYP3A)
English: Based on theoretical considerations DRV/COBI is expected to increase these beta-blocker plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih beta-blokatora. (inhibicija CYP2D6)
English: Rabeprazole
Croatian: Okskarbazepin
English: CD4+ cell count mean change from baseline
Croatian: Srednja vrijednost promjene broja CD4+ stanica od početne vrijednosti
English: Based on theoretical considerations co-administration of DRV/COBI with dabigatran or ticagrelor may increase concentrations of the anticoagulant.
Croatian: Na temelju teorijskih razmatranja, istodobna primjena kombinacije DRV/KOBI i dabigatrana ili tikagrelora mogla bi povisiti koncentracije antikoagulansa. (inhibicija CYP3A i/ili P-glikoproteina).
English: Based on theoretical considerations these antimycobacterials are expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će ovi antimikobakterijski lijekovi sniziti plazmatske koncentracije darunavira i/ili kobicistata i/ili tenofoviralafenamida. (indukcija CYP3A i/ili P-glikoproteina)
English: Clinical monitoring is recommended when co-administering Symtuza with these analgesics.
Croatian: Kod istodobne primjene lijeka Symtuza i ovih analgetika preporučuje se kliničko praćenje.
English: Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are co-administered with Symtuza.
Croatian: Kod istodobne primjene navedenih lijekova i lijeka Symtuza preporučuje se kliničko praćenje terapijskih učinaka i nuspojava.
English: Based on theoretical considerations DRV/COBI is expected to increase these PDE-5 inhibitor plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih inhibitora PDE5. (inhibicija CYP3A)
English: Based on MH test adjusting for bPI at screening (ATV with rtv or COBI, DRV with rtv or COBI, LPV with rtv)
Croatian: Temeljeno na MH testu podešavajući za bPI na probiru (ATV s rtv ili KOBI, DRV s rtv ili KOBI, LPV s rtv) Raspon oko 48. tjedna: 295. dan - 378. dan; raspon oko 96. tjedna: 631. dan - 714. dan
English: Based on theoretical considerations DRV/COBI may alter norethindrone plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, DRV/KOBI može promijeniti plazmatske koncentracije noretindrona.
English: Clinical monitoring is recommended when co-administering Symtuza with corticosteroids.
Croatian: Kod istodobne primjene lijeka Symtuza i kortikosteroida preporučuje se kliničko praćenje.
English: Based on theoretical considerations these anticonvulsants are expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će ovi antikonvulzivi sniziti plazmatske koncentracije darunavira i/ili kobicistata i/ili tenofoviralafenamida. (indukcija CYP3A i/ili P-glikoproteina)
English: Based on theoretical considerations DRV/COBI is expected to increase salmeterol plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije salmeterola. (inhibicija CYP3A)
English: Do not operate machines or drive if you feel dizzy after taking Symtuza.
Croatian: Ako nakon uzimanja lijeka Symtuza osjetite omaglicu, nemojte raditi sa strojevima niti upravljati vozilom.
English: Based on theoretical considerations DRV/COBI is expected to increase these antiarrhythmic plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih antiaritmika. (inhibicija CYP3A)
English: Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration with Symtuza occurs.
Croatian: Kod istodobne primjene s lijekom Symtuza mora se provoditi terapijsko praćenje koncentracije imunosupresiva.
English: Dabigatran, ticagrelor to help stop the clumping of platelets in the treatment of patients with a history of a heart attack
Croatian: Avanafil za liječenje erektilne disfunkcije dabigatran, tikagrelor za pomoć pri zaustavljanju zgrušavanja krvnih pločica u liječenju bolesnika koji su preboljeli srčani udar naloksegol liječenje zatvora uzrokovanog opioidima dapoksetin liječenje prijevremene ejakulacije domperidon liječenje mučine i povraćanja
English: Co-administration of Symtuza and bosentan is not recommended.
Croatian: Ne preporučuje se istodobna primjena lijeka Symtuza i bosentana.
English: Based on theoretical considerations DRV/COBI is expected to increase simeprevir plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije simeprevira.
English: 3 (range:
Croatian: n (%)
English: Cobicistat
Croatian: Klorazepat
English: Ethinyl estradiol
Croatian: NA BAZI ESTROGENA
English: Based on theoretical considerations DRV/COBI is expected to increase digoxin plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije digoksina. (inhibicija P-glikoproteina)
English: Co-administration of Symtuza with oxcarbazepine is not recommended.
Croatian: Ne preporučuje se istodobna primjena lijeka Symtuza i okskarbazepina.
English: There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with HIV PIs.
Croatian: A i B liječenih inhibitorima HIV proteaze prijavljeno je pojačano krvarenje, uključujući kožne hematome i hemartrozu.
English: Nizatidine
Croatian: ANTACIDI
English: • Remove the unscrewed cap.
Croatian: • Skinite zatvarač.
English: Lovastatin, simvastatin and lomitapide to lower cholesterol levels
Croatian: biljni lijek koji se koristi za liječenje depresije lovastatin, simvastatin i lomitapid za snižavanje razina kolesterola triazolam ili midazolam (koji se uzima kroz usta)
English: Based on theoretical considerations DRV/COBI is expected to increase lumefantrine plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije lumefantrina. (inhibicija CYP3A)
English: Based on theoretical considerations DRV/COBI is expected to increase these corticosteroid plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih kortikosteroida. (inhibicija CYP3A)
English: Ask your doctor if you are unsure about the severity of your liver disease.
Croatian: Ako niste sigurni u težinu jetrene bolesti, obratite se svom liječniku.
English: It is not recommended to co-administer Symtuza with boceprevir.
Croatian: Ne preporučuje se istodobna primjena lijeka Symtuza i boceprevira.
English: Based on theoretical considerations clarithromycin is expected to increase darunavir and/or cobicistat plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije kolhicina. (inhibicija CYP3A i/ili P-glikoproteina)
English: Based on theoretical considerations St. John's wort is expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će gospina trava sniziti plazmatske koncentracije darunavira i/ili kobicistata i/ili tenofoviralafenamida. (indukcija CYP3A i/ili P-glikoproteina)
English: Based on theoretical considerations DRV/COBI is expected to increase these immunosuppressant plasma concentrations.
Croatian: Na temelju teorijskih razmatranja, očekuje se da će DRV/KOBI povisiti plazmatske koncentracije ovih imunosupresiva. (inhibicija CYP3A)
English: Felodipine
Croatian: Lanzoprazol
English: A higher dose may be needed in children.
Croatian: U djece može biti potrebna veća doza.
English: Further information on NovoSeven can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/novoseven.
Croatian: Više informacija o lijeku NovoSeven nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/novoseven.
English: The main measure of effectiveness was the number of bleeding episodes that were controlled effectively.
Croatian: Glavno mjerilo učinkovitosti bio je broj epizoda krvarenja koje su učinkovito kontrolirane.
English: Patients or carers may be able to give NovoSeven themselves after suitable training.
Croatian: Bolesnici ili njegovatelji mogu sami davati NovoSeven nakon što prođu odgovarajuću obuku za to.
English: It is used in patients with the following conditions:
Croatian: Primjenjuje se za liječenje sljedećih stanja:
English: It activates another factor called factor X, which starts the clotting process.
Croatian: On aktivira drugi faktor zvani faktor X, koji pokreće proces zgrušavanja.
English: NovoSeven (eptacog alfa)
Croatian: NovoSeven (eptakog alfa)
English: • congenital factor VII deficiency;
Croatian: • prirođenog nedostatka faktora VII;
English: What measures are being taken to ensure the safe and effective use of NovoSeven?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka NovoSeven?
English: What is NovoSeven and what is it used for?
Croatian: Što je NovoSeven i za što se primjenjuje?
English: Other information about NovoSeven
Croatian: Ostale informacije o lijeku NovoSeven
English: However the following side effects may affect between 1 and 10 patients in 1,000: venous thromboembolic events (problems caused by blood clots in the veins), rash, pruritus (itching), urticaria (hives), fever and reduced effectiveness of treatment.
Croatian: Međutim, sljedeće nuspojave mogu se javiti u 1 do 10 na 1 000 bolesnika: događaji venske tromboembolije (poteškoće koje uzrokuju krvni ugrušci u venama), osip, pruritus (svrbež), urtikarija (koprivnjača), vrućica i smanjena učinkovitost liječenja.
English: In the body, factor VII is involved in blood clotting.
Croatian: Faktor VII u tijelu sudjeluje u procesu zgrušavanja krvi.
English: Because factor VII acts directly on factor X, independently from factors VIII and IX, NovoSeven can be used in haemophilia patients who have developed inhibitors to factor VIII or IX.
Croatian: Zbog toga što faktor VII izravno djeluje na faktor X, neovisno o faktorima VIII i IX, NovoSeven se može primjenjivati u bolesnika s hemofilijom koji su razvili inhibitore faktora VIII ili IX.
English: Side effects reported with NovoSeven are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek NovoSeven pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoSeven have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka NovoSeven nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: NovoSeven must not be used in people who are hypersensitive (allergic) to eptacog alfa, to mouse, hamster or cow proteins, or to any of the other ingredients.
Croatian: NovoSeven se ne smije upotrebljavati kod osoba koje su preosjetljive (alergične) na eptakog alfa, proteine miša, hrčka ili krave te na bilo koji drugi sastojak.
English: • Glanzmann's thrombasthenia (a rare bleeding disorder) who cannot be treated with a transfusion of platelets (components that help the blood to clot).
Croatian: • Glanzmannove trombastenije (rijetkog poremećaja krvarenja) koji se ne može liječiti transfuzijom trombocita (krvnih tjelešaca koja pospješuju zgrušavanje krvi).
English: As for all medicines, data on the use of NovoSeven are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka NovoSeven kontinuirano se prate.
English: Data on the use of NovoSeven in patients with Glanzmann's thrombasthenia were obtained from a registry of patients treated with the medicine, which showed that treatment with NovoSeven was successful in 79% of the bleeding episodes (262 out of 333) and 88% of the surgeries (140 out of
Croatian: Podatci o primjeni lijeka NovoSeven u bolesnika s Glanzmannovom trombastenijom dobiveni su iz registra bolesnika liječenih tim lijekom, a pokazali su da je liječenje lijekom NovoSeven bilo uspješno u 79 % epizoda krvarenja (262 od 333) i u 88 % kirurških zahvata (140 od 159).
English: 270 micrograms/kg may be used in adults with a mild or moderate bleeding episode.
Croatian: Jednokratna doza od 270 mikrograma/kg može se primijeniti u odraslih osoba s blagom ili umjerenom epizodom krvarenja.
English: What are the risks associated with NovoSeven?
Croatian: Koji su rizici povezani s lijekom NovoSeven?
English: An overview of NovoSeven and why it is authorised in the EU
Croatian: Pregled informacija o lijeku NovoSeven i zašto je odobren u EU-u
English: By activating factor X, NovoSeven is able to give temporary control of the bleeding disorder.
Croatian: Aktivacijom faktora X lijek NovoSeven može privremeno omogućiti kontrolu poremećaja krvarenja.
English: NovoSeven received a marketing authorisation valid throughout the EU on 23 February 1996.
Croatian: Lijek NovoSeven je dobio odobrenje za stavljanje u promet koje je na snazi u EU-u od 23. veljače
English: The European Medicines Agency decided that NovoSeven's benefits are greater than its risks and it can be authorised in the EU..
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka NovoSeven nadmašuju s njim povezane rizike te da lijek može biti odobren u Europskoj uniji.
English: • In factor VII deficiency, the dose is 15 to 30 micrograms/kg every 4 to 6 hours until the bleeding is controlled.
Croatian: • Kod nedostatka faktora VII, doza iznosi 15 do 30 mikrograma/kg svakih 4 do 6 sati sve dok se krvarenje ne stavi pod kontrolu.
English: Eptacog alfa works in the same way as factor VII.
Croatian: Eptakog alfa djeluje jednako kao faktor VII.
English: • In Glanzmann's thrombasthenia, the dose is 90 micrograms/kg every 2 hours, for at least three doses.
Croatian: • Kod Glanzmannove trombastenije, doza je 90 mikrograma/kg svaka 2 sata, a daju se najmanje tri doze.
English: In a study involving 61 haemophilia patients with inhibitors, 84% of the 57 serious bleeds and 59% of the 38 surgical bleeds were controlled effectively with NovoSeven.
Croatian: U ispitivanju kojim je obuhvaćen 61 bolesnik koji boluje od hemofilije s inhibitorima, 84 % od 57 teških krvarenja i 59 % od 38 kirurških krvarenja bili su učinkovito kontrolirani lijekom NovoSeven.
English: NovoSeven can only be obtained with a prescription and treatment and should be started under the supervision of a doctor who has experience in the treatment of haemophilia or bleeding disorders.
Croatian: NovoSeven se izdaje samo na liječnički recept, a liječenje je potrebno započeti pod nadzorom liječnika s iskustvom u liječenju hemofilije ili poremećajâ krvarenja.
English: For more information about using NovoSeven, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka NovoSeven pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Why is NovoSeven authorised in the EU?
Croatian: Zašto je lijek NovoSeven odobren u EU-u?
English: NovoSeven is a medicine used to treat and to prevent bleeding after surgical procedures.
Croatian: NovoSeven je lijek za liječenje i sprečavanje krvarenja nakon kirurških zahvata.
English: In another study in 60 patients with mild to moderate bleeding episodes, which investigated whether NovoSeven could be used in the home setting, 90% of the bleeding episodes were controlled effectively.
Croatian: U drugom ispitivanju kojim je obuhvaćeno 60 bolesnika s blagim do umjerenim epizodama krvarenja, u kojem je ispitivano može li se NovoSeven primijeniti u kućnom okruženju, 90 % epizoda krvarenja bilo je učinkovito kontrolirano.
English: • congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘inhibitors' (antibodies) against factor VIII or IX;
Croatian: • prirođene hemofilije (poremećaja krvarenja koji je prisutan od rođenja) u bolesnika kod kojih su se razvili ili se očekuje da će se razviti „inhibitori” (protutijela) protiv faktora VIII ili IX;
English: NovoSeven can also be used to replace the missing factor VII in patients with factor VII deficiency.
Croatian: NovoSeven se može primjenjivati i kao nadomjestak faktora VII u bolesnika s nedostatkom faktora VII.
English: • In haemophilia, the dose is 90 micrograms per kilogram body weight, repeated every 2 to 3 hours until the bleeding is controlled.
Croatian: • Kod hemofilije doza je 90 mikrograma po kilogramu tjelesne težine, što se ponavlja svaka 2 do 3 sata sve dok se krvarenje ne stavi pod kontrolu.
English: The active substance in NovoSeven, eptacog alfa, is almost identical to a human protein called factor VII.
Croatian: Djelatna tvar u lijeku NovoSeven, eptakog alfa, gotovo je identična ljudskom proteinu faktor VII.
English: • acquired haemophilia (a bleeding disease caused by the development of inhibitors to factor VIII);
Croatian: • stečene hemofilije (bolesti krvarenja koju uzrokuje razvoj inhibitora faktora VIII);
English: What benefits of NovoSeven have been shown in studies?
Croatian: Koje su koristi od lijeka NovoSeven utvrđene u ispitivanjima?
English: NovoSeven has been studied in patients with haemophilia and in patients with factor VII deficiency.
Croatian: NovoSeven je ispitivan u bolesnika s hemofilijom i u bolesnika s nedostatkom faktora VII.
English: Side effects with NovoSeven are not common.
Croatian: Nuspojave lijeka NovoSeven nisu česte.
English: It is available as a powder and solvent that are made up into a solution to be injected into a vein.
Croatian: Dostupan je u obliku praška i otapala za pripremu otopine za infuziju (drip) u venu.
English: How does NovoSeven work?
Croatian: Kako djeluje NovoSeven?
English: How is NovoSeven used?
Croatian: Kako se NovoSeven primjenjuje?
English: NovoSeven contains the active substance eptacog alfa.
Croatian: Lijek NovoSeven sadrži djelatnu tvar eptakog alfa.
English: For the full list of side effects of NovoSeven, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka NovoSeven potražite u uputi o lijeku.
English: 1 After reconstitution, 1 dose (0.2 ml) contains:
Croatian: 1 Nakon rekonstitucije, 1 doza (0,2 ml) sadrži:
English: This product contains genetically modified organisms (GMOs).
Croatian: Ovaj proizvod sadrži genetski modificirane organizme (GMO). jedinice fluorescentnog žarišta
English: propagated in fertilised hens' eggs from healthy chicken flocks.
Croatian: umnoženih u oplođenim kokošjim jajima iz jata zdravih kokoši. proizvedeni u VERO stanicama tehnologijom reverzne genetike.
English: 1 (live attenuated) of the following four strains
Croatian: Reasortirani virus gripe 1 (živi oslabljeni) sljedećih četiriju sojeva
English: Pack size sprayer (glass) in trays sprayer (glass) in a tri-fold carton
Croatian: Sprej za nos, suspenzija Samo za nos raspršivač (staklo) u pakiranju s trostrukim preklopom
English: B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977)
Croatian: B/Phuket/3073/2013 - poput kojeg je korišten soj (B/Phuket/3073/2013, MEDI 254977)
English: A/Brisbane/02/2018 (H1N1)pdm09 - like strain (A/Switzerland/3330/2017, MEDI 307134)
Croatian: A/Brisbane/02/2018 (H1N1)pdm09 - poput kojeg je korišten soj (A/Switzerland/3330/2017, MEDI 307134)